Certara Fair Value Rises to US$8.71 as Analysts Weigh Turnaround

Simply Wall St··US·Read original
2▲1 ▼0Impact / 5
Summary · why it matters

Certara's fair value estimate has edged up to US$8.71 from US$8.19, with analyst price targets clustering in the US$9 to US$10 range ahead of upcoming results. UBS resumed coverage of Certara with a Neutral rating and a US$10 price target, while Barclays lifted its target from US$7.50 to US$9 and Baird moved from US$6 to US$7. Revenue growth expectations have shifted from a decline of 0.64% to an increase of 1.49%, while the net profit margin is reported at 3.76% on both the previous and updated figures and the future P/E has changed from 87.9x to 94.4x. Barclays describes an "extremely tough setup" for life science and diagnostic stocks, and UBS says it wants more evidence of a software revenue recovery before taking a more positive view. The discount rate is broadly unchanged, moving from 8.57% to 8.59%.

Impact on assets 4

Financials▲
Barclays PLC
BARC
± MixedCapitalrelevance

Barclays is cited only for lifting its Certara price target and its comment on a tough life-science setup, not as a subject of the news.

UBS Group AG
UBSG
± MixedCapitalrelevance

UBS is mentioned only for resuming Certara coverage with a Neutral rating and US$10 target, not as a subject of the news.

Biotech & Genomic Medicine▲
Certara Inc
CERT
▲ PositiveCapitalrelevance

Analyst fair value and price targets for Certara were raised (UBS US$10, Barclays US$9, Baird US$7), with revenue growth expectations shifting from a decline to an increase.

Aging Population▲

Off-coverage companies 1

Robert W. Baird & Co. Incorporatedi
Private± MixedCapitalrelevance

Baird is mentioned only for raising its Certara price target from US$6 to US$7, not as a subject of the news.